Eric Hahn is an American entrepreneur who started Collabra Software in 1992. Collabra was an early e-mail-based groupware company. Netscape acquired Collabra in 1995. In 1997 Eric became Netscape's CTO. According to SEC filings Hahn netted approximately $29 million from sales in Netscape stock. Hahn is also the creator of Lookout Software, which was acquired by Microsoft in 2004. Mr. Hahn currently lives in Palo Alto, California with his wife and two sons, …

Jeff has worked in the valley for over twenty years in a number of Silicon Valley startups. For the last 10 years he has worked as a VP of Engineering. Prior to that Jeff was an Engineering Director at Netscape and one of the founders of Collabra.

When Hahn graduated from WPI in 1980, he took a job with Bolt, Beranek and Newman (BBN), a computer services company based in Cambridge, Mass. There he helped develop ARPANET, the nationwide computer network that evolved into the Internet. After two years he was recruited to help get the start-up Convergent Technologies off the ground.

Jim Black VICE PRESIDENT, PRODUCT DEVELOPMENT Jim Black is a veteran of the messaging industry with over 20 years of experience in software engineering and management. He has expertise in large-scale system architecture, performance and scalability at both technology startups and established companies.

Brad Goodwin Chief Executive Officer and Board Member Brad Goodwin brings 25 years of pharmaceutical, business and finance experience to Novacea. Brad Goodwin brings 25 years of pharmaceutical, business and finance experience to Novacea. Prior to joining the company, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company offering pharmaceutical product licensing and development.

Nick Simon , M.B.A. Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company.

Bradford S. Goodwin joined us as a director in January 2007. Mr. Goodwin is currently a director of PDL BioPharma and until its sale in early 2007 he was also the Chairman of the Board of CoTherix, Inc., a public-traded company focused on pulmonary arterial hypertension. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea, Inc., a publicly-held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for cancer.

Brad Goodwin Chief Executive Officer and Board Member Brad Goodwin brings 25 years of pharmaceutical, business and finance experience to Novacea. Prior to joining the company, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company offering pharmaceutical product licensing and development.

Danny Shader President and CEO of Good Technology, Inc Danny Shader is president and CEO of Good Technology, Inc. Prior to Good, Mr. Shader served as a vice president and general manager at Amazon.com. Mr. Shader co-founded and was CEO of Accept.com, the first consumer-to-consumer payment services company.

Karen Richardson CEO of E.piphany Karen Richardson 's 20-year career in the software business includes positions as a key player in several well-known and highly successful companies. Prior to joining E.piphany, Ms. Richardson held senior sales positions at Netscape Communications Corporation from 1995-1998, during which time Netscape's sales grew from $80 million to over $500 million annually.

Over 17 years of experience in Software Quality Assurance with 10 years in management roles of increasing responsibility. Demonstrated successes and abilities in building and motivating an organization capable of executing the company's operating plan to deliver high quality products. Excellent teamwork with all cross functional teams. Currently, overseeing QA, Technical Operations, and Project Management at Glu Mobile.

Nicholas Simon has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 25 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 2002. From 1989 to 2000, Mr. Simon was an executive at Genentech (NYSE:DNA) where he held several positions including Vice President of Business and Corporate Development.

Bob Lisbonne , Matrix Partners Bob Lisbonne joined Matrix Partners as a General Partner in the Silicon Valley office in June 2001. Before Matrix, Lisbonne was a general partner with Crosspoint Venture Partners. Prior to Crosspoint, Lisbonne was Senior Vice President and General Manager of the browser products division at Netscape Communications. Before that he was Vice President of Marketing at Collabra Software, which was acquired in 1995 by Netscape.

Eric Hahn Founder & Chairman Eric Hahn is the founding partner of the Inventures Group, a leading "mentor investment'' firm based in Palo Alto, California. Eric Hahn is the founding partner of the Inventures Group, a leading "mentor investment'' firm based in Palo Alto, California. At Inventures, Mr. Hahn has served as a director and has been actively involved with companies including Kana, Red Hat, LoudCloud, Good Technologies, and RemarQ.

Application Developer, Database Administrator, and Project Manager in a wide variety of business applications. CEO of Collabra AB. Corporate generalist with substantial financial and personell leading experience.

Stephen J. Peroutka , M.D., Ph.D., Chief Medical Officer Stephen J. Peroutka , M.D., Ph.D., joined the Company as its Chief Medical Officer in November 2007. Dr. Peroutka is a recognized leader in the neuroscience arena. Prior to joining Zogenix, Dr. Peroutka was the Franchise Development Leader for Pain at Johnson & Johnson. From 2003-2005, he was the President and CEO of Synergia Pharma, Inc., a private biopharmaceutical company focusing on neurological disorders.

Nicholas Simon is a Managing Director at Clarus Ventures, LLC, a venture capital company he co-founded in February, 2005, which is focused on investing in life sciences companies. Since October 2001, Mr. Simon has been a General Partner at MPM BioVentures III. From April 2000 to July 2001, Mr. Simon was Chief Executive Officer, Founder, and Director of Collabra Pharma, Inc., a pharmaceutical development company.